ESTRO 2022 - Abstract Book

S505

Abstract book

ESTRO 2022

Results After median follow-up 10months (1-27) all patients are alive; 6p (12%) developed biochemical progression at a median time of 12 months (9-22) with 1y and 2y bPFS of 81.6% and 66% respectively; 4p (8%) developed clinical progression (1p local+distant metastases, 1p nodal regional and 2p distant metastases solely) at a median time of 16 months (6-22) with 1y and 2y cPFS of 97.5% and 74.3% respectively; finally, 1y and 2y DMFS were 97.5% and 83.8% respectively (Fig. 1) Acute toxicity: genitourinary G1 11p (22%), G2 4p (8%); gastrointestinal G1 9p (18%), G2 3p (6%). Late toxicity (follow-up >90 days):gastrointestinal G1 4p (8%), G2 1p (2%); genitourinary G1 5p (10%), G2 1p (2%); gastrointestinal G1 4pm (8%), G2 1p (2%)